Table S1, Table S1B, Table S2 from Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

Autor: Brenda J. Weigel, Elizabeth Fox, Joel M. Reid, Stacey L. Berg, Stephan D. Voss, Daphne A. Haas-Kogan, John M. Maris, Bruce R. Pawel, Charles G. Minard, Xiaowei Liu, Heba Ijaz, Rachel A. Kudgus, Sharmistha Pal, Kristina A. Cole
Rok vydání: 2023
Popis: S1. Patient Characteristics of eligible (n=37) and MTD/RP2D evaluable (n=27) patients S1B. Diagnosis of eligible (n=37) and MTD/RP2D evaluable (n=27) patients. S2. In Cycle 1, All Hematologic and Non-Hematologic toxicities related to protocol therapy in evaluable patients (N=27)
Databáze: OpenAIRE